 |
|
LIAI scientists make major finding on potential cure for type 1 diabetes
April 21, 2006Human clinical trials planned to begin later this year
SAN DIEGO - A major finding, which represents an important step toward a potential cure for type 1 (insulin-dependent) diabetes, has been made by a research team at the La Jolla Institute for Allergy & Immunology (LIAI). The team, led by Matthias von Herrath, M.D., an internationally recognized expert on the molecular basis of type 1 diabetes, used a combinatorial treatment approach in laboratory mice and found it reversed recent onset type 1 diabetes in the majority of animals tested.
The study, which combined two therapies (anti-CD3 antibody and proinsulin peptide) already being tested individually in human clinical trials, produced better efficacy, longer-lasting results and fewer side effects in the preclinical trials in mice than either therapy has shown alone in the human studies. The researchers hope to begin testing the combination therapy in human clinical trials later this year. Damien Bresson, a researcher in Dr. von Herrath's lab, contributed to the study. Kevan Herold, an Associate professor at Columbia University, and Jeffrey Bluestone, Director of the University of California, San Francisco Diabetes Center, were also contributors.
"The finding of increased efficacy of reversal of recent-onset type 1 diabetes in animals that received a combination of systemic anti-CD3 antibody and intranasal proinsulin peptide compared to therapy with the antibody alone is an exciting and important finding," said Richard A. Insel, M.D., Executive Vice President for Research at the Juvenile Diabetes Research Foundation.
The anti-CD3 antibody has been shown to temporarily reverse recent onset human type 1 diabetes in two independent clinical trials. The reversal was maintained for more than a year. "This combination approach is worth evaluating in human type 1 diabetes to increase both the overall efficacy of the treatment and the duration of the beneficial effect," Dr. Insel said.
The finding was published today in the online version of the Journal of Clinical Investigation in a paper, "A novel combination therapy in recent onset autoimmune diabetes: synergy of anti-CD3 and nasal proinsulin to induce Tregs." Dr. von Herrath said the human clinical trials, which still require regulatory approval, would be directed at persons recently diagnosed with type 1 diabetes or who are already being treated for pre-diabetes.
George Eisenbarth, M.D., Ph.D., Executive Director of the Barbara Davis Center for Childhood Diabetes in Colorado, called the finding "a very important discovery, demonstrating synergistic efficacy of two therapies (anti-CD3 and proinsulin immunomodulation) that are in human studies for the prevention of type 1 diabetes."
Dr. von Herrath's approach focuses on teaching the immune system to tolerate, rather than attack, the insulin-producing beta cells of the pancreas. By injecting the anti-CD3 antibody, which calms the immune system and lessens the attack on the beta cells, along with a piece of the nasal proinsulin peptide, which acts like a vaccine and induces a special cell type called "regulatory cells" that can actively and highly specifically protect beta cells, Dr. von Herrath was able to stop the immune system's destruction of the beta cells in mice.
Combining the two therapies produced a "strong synergy," he said. "The combinatorial approach doubled the efficacy in laboratory mice - with fewer side effects than using either one alone." The study represented the first time a combinatorial treatment approach using a vaccine strategy had ever been tried in type 1 diabetes. Dr. von Herrath added that the combined therapy also showed long-lasting results. "The diabetes never reoccurred in the lifespan of the mice."
Mitchell Kronenberg, Ph.D, LIAI President and Scientific Director, said the therapy is "particularly attractive because - if successful in humans - it could replace current insulin-injection treatments altogether, which often cannot prevent the long-term detrimental effects of diabetes." Type 1 diabetes, also called insulin-dependent diabetes or juvenile diabetes, occurs when the immune system mistakenly destroys the insulin-producing beta cells of the pancreas, which are key to controlling blood sugar levels. As a result, type 1 diabetes sufferers inject insulin daily to control blood sugar levels. However, complete control is difficult to achieve and damage to body organ systems can still occur. Complications from type 1 diabetes can include kidney failure, adult blindness and the need for amputations.
"Since the complications from high blood sugar levels (diabetes) worsen with time, we are hopeful that this therapy can reverse the disease in patients before they have too much multi-organ damage," Dr. von Herrath said.
La Jolla Institute for Allergy and Immunology
"The finding of increased efficacy of reversal of recent-onset type 1 diabetes in animals that received a combination of systemic anti-CD3 antibody and intranasal proinsulin peptide compared to therapy with the antibody alone is an exciting and important finding," said Richard A. Insel, M.D., Executive Vice President for Research at the Juvenile Diabetes Research Foundation.
The anti-CD3 antibody has been shown to temporarily reverse recent onset human type 1 diabetes in two independent clinical trials. The reversal was maintained for more than a year. "This combination approach is worth evaluating in human type 1 diabetes to increase both the overall efficacy of the treatment and the duration of the beneficial effect," Dr. Insel said.
The finding was published today in the online version of the Journal of Clinical Investigation in a paper, "A novel combination therapy in recent onset autoimmune diabetes: synergy of anti-CD3 and nasal proinsulin to induce Tregs." Dr. von Herrath said the human clinical trials, which still require regulatory approval, would be directed at persons recently diagnosed with type 1 diabetes or who are already being treated for pre-diabetes.
George Eisenbarth, M.D., Ph.D., Executive Director of the Barbara Davis Center for Childhood Diabetes in Colorado, called the finding "a very important discovery, demonstrating synergistic efficacy of two therapies (anti-CD3 and proinsulin immunomodulation) that are in human studies for the prevention of type 1 diabetes."
Dr. von Herrath's approach focuses on teaching the immune system to tolerate, rather than attack, the insulin-producing beta cells of the pancreas. By injecting the anti-CD3 antibody, which calms the immune system and lessens the attack on the beta cells, along with a piece of the nasal proinsulin peptide, which acts like a vaccine and induces a special cell type called "regulatory cells" that can actively and highly specifically protect beta cells, Dr. von Herrath was able to stop the immune system's destruction of the beta cells in mice.
Combining the two therapies produced a "strong synergy," he said. "The combinatorial approach doubled the efficacy in laboratory mice - with fewer side effects than using either one alone." The study represented the first time a combinatorial treatment approach using a vaccine strategy had ever been tried in type 1 diabetes. Dr. von Herrath added that the combined therapy also showed long-lasting results. "The diabetes never reoccurred in the lifespan of the mice."
Mitchell Kronenberg, Ph.D, LIAI President and Scientific Director, said the therapy is "particularly attractive because - if successful in humans - it could replace current insulin-injection treatments altogether, which often cannot prevent the long-term detrimental effects of diabetes." Type 1 diabetes, also called insulin-dependent diabetes or juvenile diabetes, occurs when the immune system mistakenly destroys the insulin-producing beta cells of the pancreas, which are key to controlling blood sugar levels. As a result, type 1 diabetes sufferers inject insulin daily to control blood sugar levels. However, complete control is difficult to achieve and damage to body organ systems can still occur. Complications from type 1 diabetes can include kidney failure, adult blindness and the need for amputations.
"Since the complications from high blood sugar levels (diabetes) worsen with time, we are hopeful that this therapy can reverse the disease in patients before they have too much multi-organ damage," Dr. von Herrath said.
La Jolla Institute for Allergy and Immunology
Type 1 Diabetes Current Events and Type 1 Diabetes News RSSUM Scientists Create Fruit Fly Model to Help Unravel Genetics of Human Diabetes
As rates of obesity, diabetes, and related disorders have reached epidemic proportions in the US in recent years, scientists are working from many angles to pinpoint the causes and contributing factors involved in this public health crisis.
Vegetables can protect unborn child against diabetes
New evidence is emerging for how important it is for pregnant women to eat good, nutritious food. Expecting mothers who eat vegetables every day seem to have children who are less likely to develop type 1 diabetes, a new study from the Sahlgrenska Academy has revealed.
Protein critical for insulin secretion may be contributor to diabetes
A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.
Diabetic Episodes Affect Kids' Memory
Children who have had an episode of diabetic ketoacidosis, a common complication of diabetes, may have persistent memory problems, according to a new study from researchers at the UC Davis Center for Mind and Brain.
A major step in making better stem cells from adult tissue
October 15, 2009 A team led by scientists from The Scripps Research Institute has developed a method that dramatically improves the efficiency of creating stem cells from human adult tissue, without the use of embryonic cells.
Blood counts are clues to human disease
A new genome-wide association study published today in Nature Genetics begins to uncover the basis of genetic variations in eight blood measurements and the impact those variants can have on common human diseases.
Self-monitoring of blood glucose
Diabetes patients should always control their own blood sugar values if this leads to improvements in their treatment.
Is inhaled insulin delivery still a possibility? Why has it been a commercial failure?
The commercial failure of Exubera® (Pfizer, New York, NY), the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market.
Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award
A scientist at the La Jolla Institute for Allergy & Immunology has received one of the National Institutes of Health (NIH)'s top awards -- the 2009 NIH Director's Pioneer Award.
JDRF-funded studies show regular CGM use increases diabetes control for all age groups
The latest data from groundbreaking human clinical trials of the effectiveness of continuous glucose monitors (CGM) show that the primary determinant of improvements in achieving better diabetes control is regular use of monitors - six days per week or more - rather than the age of patients, and that benefits continue well past the time when people with type 1 diabetes begin using the devices - including experiencing fewer low blood sugar emergencies.
More Type 1 Diabetes Current Events and Type 1 Diabetes News Articles
 |
Type 1 Diabetes: A Guide for Children, Adolescents, Young Adults--and Their Caregivers, Third Edition by M.D. Ragnar Hanas M.D. (Author), Ph.D. Stuart Brink Ph.D. (Foreword), Jeff Hitchcock (Foreword) Living with type 1 diabetes requires intensive, nonstop daily management, week after week, year after year. This means that young people with type 1 and their parents have to become experts on their own condition—even better informed than the average doctor—and able to self-manage its daily demands. The Type 1 Diabetes Book is the most authoritative book ever published on the condition and will become the one book that every young person with type 1 diabetes will need to own. "In this book," writes author Dr. Ragnar Hanas, "I speak directly, all the time, to you, the person with diabetes. The topics covered range from how your body works to sweets, treats, and ice cream; from insulin injection technique to long-term complications; and any number of subjects in between. With this book... |
 |
Type 1 Diabetes For Dummies (For Dummies (Health & Fitness)) by Alan L. Rubin MD (Author) Whether you have been living with type 1 diabetes for some time, or you have just discovered that your child is diabetic, there’s a lot you need to know about the new developments in treating, controlling, and living with this disease. Type 1 Diabetes For Dummies, explains everything you need to know and do to make living with type 1 diabetes easier and healthier. This reassuring, plain-English guide helps you understand and mange the disease with tips on working with your doctor, administering insulin, developing a diet an exercise plan, and coping with illness and travel. You’ll find out about the latest technologies of blood glucose monitoring and insulin delivery, and get a handle on everything you need to do to keep yourself or your child healthy, active, and feeling... |
 |
Hypoglycemia Symptoms Alarm - Diabetes watch - NO ONGOING COSTS by Giant Biosensor Detects two symptoms of hypoglycemia and awakens you during sleep. Not for sale in USA The Hypoglycemia Symptoms Alarm is a sleep monitor for symptoms of hypoglycemia. It's a device worn on the wrist or ankle that sounds an audible alarm and vibrates to wake those people with insulin dependent diabetes who suffer from nocturnal hypoglycemia (low blood sugar while sleeping) commonly referred to as an insulin reaction and either don't wake up, or don't wake up soon enough to take corrective action. It triggers an alert upon detecting the presence of perspiration or a decrease in skin temperature, two common symptoms associated with hypoglycemia. Features of the Hypoglycemia Symptoms Alarm include a sleek, ergonomic design and a comfortable adjustable elastic strap. Other than the... |
|
Pathophysiology of Type 1 Diabetes Starring: Concept Media Inc. | |
 |
T-1 Luminary Bags by LumaBase Four years ago, Harrison was diagnosed with Type 1 Diabetes. At the age of seven Harrison realized that people dont really know about the unique characteristics of Type 1. Harrison has made it his goal to enlighten the Nation, and next year the world, to the realities of Type 1. This is an exciting event for everyone touched by Type 1 diabetes because, for one day, the entire Nation will be enlightened about just Type 1. There is no other event where you can reach so many people who would not normally have any interest to ask about Type 1. People who are not aware of the event will be curious why your town is lit up with T-1 luminaries. The accompanying Type 1 factsheet gives everyone an opportunity to explain the misconceptions, articulate the need for a cure and support kids with Type 1... |
 |
Appraise Hemoglobin A1C Home Test Kit by Appraise INDICATIONS: Appraise diabetes A1c home test kit, 90462. Clinically accurate information you can use with your Healthcare provider to assess your daibetes treatment plan. |
|
Medical Management of Type 1 Diabetes by American Diabetes Association (ADA) (Author) Featuring a recommended course of diagnosing and treating patients with type 1 diabetes A comprehensive resource for health care professionals that outlines the American Diabetes Association’s recommended course of diagnosing and treating patients with type 1 diabetes. This comprehensive volume provides the basis for individualized, flexible, responsive treatment plans for patients with type 1 diabetes. It includes integrated approaches on blood pressure and lipid goals, proper nutrition, exercise, smoking cessation, and more. All based on the clinical practice recommendations of the American Diabetes Association. | |
 |
Additional Notes On Managing Type 1 Diabetes Diabetes Prevention Society (Primary Contributor) |
 |
BMV Quantum Subliminal CD Diabetes Aid (Ultrasonic Peak Health Series) Program your subconscious mind to overcome diabetes and alleviate diabetic symptoms. Improve your health, self-healing and overall physical wellbeing. Create results using state-of-the-art subliminal and brainwave entrainment technology. Tune your brainwaves to specific frequencies by listening to this CD! Program your subconscious mind for positive lasting results, created by a Certified Hypnotherapist and NLP Practitioner (Neuro-Linguistic Programming). Silent affirmations, inaudible hypnotic suggestions and thousands of powerful subliminal messages program your subconscious mind for positive results. The first 3 tracks have an ocean background. The Silent Ultrasonic Track 4 is completely silent with no sound at all! BMV exclusive Quantum Subliminal Matrix Technology sets a new standard... |
|
A Sugar-Free Cube by Jessica Hickok A personal melting pot of all things related to real estate, property management and living life with type 1 diabetes in Springfield, Missouri. It's all mixed up with a dash of sarcasm and a few morsels of good web 2.0 tips and tricks.Kindle blogs are fully downloaded onto your Kindle so you can read them even when you're not wirelessly connected. And unlike RSS readers which often only provide headlines, blogs on Kindle give you full text content and images, and are updated wirelessly throughout the day. |
| © 2009 BrightSurf.com |